Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue

Table 1 Participants’ characteristics

ID#	Clinical diagnosis	Pathological diagnosis	Age at death (yrs)	Gender	PMI (hrs)	Braak & Braak (NFT)	CERAD score (neuritic plaques)	NIA-Reagan Institute criteria
#1	CTL	Normal adult brain	86	M	10	I	none	LP
#2	CTL	Normal adult brain	73	F	20	I	none	LP
#3	CTL	Normal adult brain	101	F	22	II	A	LP
#4	AD	AD	96	F	20	V	C	HP
#5	AD	AD	78	F	18	VI	C	HP
#6	AD	AD	97	F	12	VI	A	HP
#7	AD	AD	87	F	12	IV	B	IP
#8	AD	AD	60	M	24	VI	C	HP
#9	AD	AD	82	F	6	V	B	HP
#10	AD	AD	69	F	4	VI	C	HP
#11	AD	AD	70	M	6	V	C	HP
#12	AD	AD	66	F	2	VI	C	HP
#13	AD	AD	66	F	10	VI	C	HP
#14	AD	AD	97	F	24	V	C	HP
#15	AD	AD	81	M	7	IV	C	IP
#16	FTLD	AD/CAA	66	M	16	V	B	HP
#17	Memory, speech and gait difficulties, hand tremor	Diffuse CAA (D23N Iowa APP mutation)	45	M	N/A	I	none	LP
#18	AD	AD/Metastatic melanoma	75	M	35	V	B	IP
#19	FTLD	PiD, type A	61	M	19	N/A	N/A	N/A
#20	FTLD	PiD	62	M	19	I	A	LP
#21	FTLD (P301L Mutation)	FTLD	71	F	4	I	none	LP
#22	FTLD	DLDH	65	M	24	I	none	LP
#23	CBD	CBD	80	M	6	I	none	LP
#24	PSP	PSP	69	M	45	II	none	LP
#25	PSP	PSP	68	M	48	II	none	LP
#26	PSP	PSP	78	M	11	II	none	LP
#27	PSP	PSP	73	M	12	II	none	LP
#28	PSP	PSP	63	F	12	II	none	LP
#29	CTE	CTE (CTE stage II-III) [23]	25	M	27	0	none	LP
#30	CTE	CTE (CTE stage III)	56	M	N/A	II	none	LP
#31	CTE	CTE (CTE stage III)	46	M	72	III	none	LP
#32	CTE	CTE (CTE stage IV)	65	M	N/A	II	A	LP
#33	CTE	CTE (CTE stage III)	58	M	N/A	III	none	LP
#34	DLB	LBD	62	M	24	N/A	none	N/A
#35	DLB	LBD, brainstem predominant	76	M	17	II	none	LP
#36	PDD	LBD (Braak stage 4/6)	83	M	9	III	none	LP
#37	MSA	MSA, cerebellar type (MSA-C)	60	F	32	II	none	LP
#38	FTLD	FTLD-TDP-43, type A	69	F	16	I	none	LP
#39	FTLD	FTLD-TDP-43	55	M	14	I	none	LP
#40	FTLD	FTLD-TDP-43	68	M	49	I	none	LP
#41	FTLD	FTLD-TDP-43	64	M	12	I	none	LP
#42	Headache	Subarachnoid hemorrhage	92	F	N/A	IV	A	IP
#43	N/A	Parenchymal hemorrhage	75	M	N/A	I	none	LP

Abbreviations: AD Alzheimer’s disease, APP amyloid precursor protein, CAA Cerebral amyloid angiopathy, CBD Corticobasal degeneration, CERAD Consortium to establish a registry for Alzheimer’s disease, CTL Control subject, DLB Dementia with lewy bodies, DLDH Dementia lacking distinctive histopathology, F Female, FTLD Frontotemporal lobar degeneration, HP High probability, IP Intermediate probability, LP Low probability, M Male, MSA Multiple systemic atrophy, NFT Neurofibrillary tangles, NIA National Institute of Aging, N/A Non available, PiD Pick’s disease, PMI Postmortem interval, PSP Progressive supranuclear palsy, TDP-43 TAR DNA binding protein 43

ISSN: 2051-5960